Episode Details
Back to Episodes
Johnson and Johnson Steady Above $200 Amid Positive Analyst Tweaks and Revenue Growth
Published 4 months, 2 weeks ago
Description
# Johnson & Johnson (JNJ) Stock Analysis: Analyst Upgrades & Revenue Growth - Quiet Please Finance Podcast
Explore the latest developments in Johnson & Johnson's stock performance in our newest podcast episode. We break down JNJ's recent trading activity, with shares closing at $211.58 on December 12, 2025, before climbing to $214.17 on December 15 with trading volume of 8.47 million shares—slightly below the daily average of 8.89 million.
Discover why major financial institutions are bullish on JNJ, with Bank of America raising their price target to $220, Barclays increasing to $197, and Guggenheim setting an ambitious $227 target with a "buy" rating. We analyze what's behind the consensus "moderate buy" rating and the $208.35 price target from Wall Street analysts.
Our episode also covers JNJ's impressive Q3 2025 performance, featuring revenue of $24 billion (up 6.77% year-over-year), its substantial $516 billion market cap, attractive P/E ratio of 20.7, and compelling 2.54% dividend yield.
Whether you're a current shareholder or considering adding this healthcare giant to your portfolio, this episode provides the essential data and expert analysis you need to make informed investment decisions. Subscribe to Quiet Please Finance for more market insights and stock analysis at quietplease.ai.
#JohnsonAndJohnson #StockAnalysis #InvestmentTips #MarketOutlook #DividendStocks #FinancialPodcast
For more http://www.quietplease.ai
Stock up on these deals
https://amzn.to/3QFpYIX
This content was created in partnership and with the help of Artificial Intelligence AI
This episode includes AI-generated content.
Explore the latest developments in Johnson & Johnson's stock performance in our newest podcast episode. We break down JNJ's recent trading activity, with shares closing at $211.58 on December 12, 2025, before climbing to $214.17 on December 15 with trading volume of 8.47 million shares—slightly below the daily average of 8.89 million.
Discover why major financial institutions are bullish on JNJ, with Bank of America raising their price target to $220, Barclays increasing to $197, and Guggenheim setting an ambitious $227 target with a "buy" rating. We analyze what's behind the consensus "moderate buy" rating and the $208.35 price target from Wall Street analysts.
Our episode also covers JNJ's impressive Q3 2025 performance, featuring revenue of $24 billion (up 6.77% year-over-year), its substantial $516 billion market cap, attractive P/E ratio of 20.7, and compelling 2.54% dividend yield.
Whether you're a current shareholder or considering adding this healthcare giant to your portfolio, this episode provides the essential data and expert analysis you need to make informed investment decisions. Subscribe to Quiet Please Finance for more market insights and stock analysis at quietplease.ai.
#JohnsonAndJohnson #StockAnalysis #InvestmentTips #MarketOutlook #DividendStocks #FinancialPodcast
For more http://www.quietplease.ai
Stock up on these deals
https://amzn.to/3QFpYIX
This content was created in partnership and with the help of Artificial Intelligence AI
This episode includes AI-generated content.